---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-033614"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:49:29.427710+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Contineum reports Q3 2024 cash $213.9M, VISTA trial enrollment on track

## Summary
- Cash, equivalents and marketable securities $213.9M as of Sept 30, 2024 (vs $125.2M at end of 2023).
- R&D expense $9.7M (+$3.2M YoY) driven by VISTA Phase 2 trial and PIPE-791 toxicology studies.
- VISTA trial for PIPE-307 in RRMS two-thirds enrolled; full enrollment expected first half 2025.
- Pending MHRA authorization, Phase 1b PET trial for PIPE-791 to start Dec 2024 with data in H1 2025.
- Janssen confirms on track to initiate Phase 2 trial of PIPE-307 in depression.

## SEC filing metadata
- accession: 0001437749-24-033614
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000143774924033614/0001437749-24-033614-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000143774924033614/cont20241029_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-033614
- JSON: https://secwatch.observer/filing/0001437749-24-033614.json
- Plain text: https://secwatch.observer/filing/0001437749-24-033614.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.